NEX-I
Founded 2021 · $63.7M raised
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Total Funding
- $63.7M
- Last Round
- $3.6M Pre-SeedAug 2025
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Next-generation Immunotherapeutics
Summary
NEX-I is a Biotech company, founded in 2021. It has raised $63.7M in total across 3 rounds, most recently a $3.6M Pre-Seed round in Aug 2025. Investors include DSC Investment, Atinum Investment and Hana Ventures.
Funding History
Aug 2025
Sign up to see all 3 events
Funding: Series B. Amounts, valuations, and investors where available.
Investors
DSC Investment
3 rounds
Atinum Investment
2 rounds
Hana Ventures
2 rounds
Stonebridge Capital
1 round
TS Investment
1 round
CJ Investment
1 round
WONIK Investment Partners
1 round
KB Investment
1 round
AJU IB Investment
1 round
Quad Partners
1 round
Horizon Partners
1 round
Company K Partners
1 round
Korea Investment & Securities
1 round
Industrial Bank of Korea
1 round
Yuanta Investment
1 round
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nex-i"><img src="https://indexed.vc/api/badge/company/nex-i" alt="NEX-I on Indexed.vc" width="260" height="76" /></a>